Global Navigation
Country reports
Date Published: 27 Jan 2012
Currently facing a major financial crisis, Spain's healthcare system is overstretched with autonomous regions owing millions of Euros to suppliers such as the pharma industry
Date Published: 19 Dec 2011
France's market strength, political stability and solid investment outweigh concerns such as heavy taxation, price controls and new regulations that limit profitability for pharma companies
Date Published: 23 Nov 2011
Brazil is an attractive market for investors and a 'growth pole' in Latin America, set to become a leading economic powerhouse
Country report: Czech Republic
Date Published: 27 Oct 2011
In the Czech Republic, the pharmaceutical industry is the third-largest sector in terms of share of GDP, accounting for approximately 13 per cent of the country’s industrial production
Date Published: 30 Sep 2011
There has been a radical shift in the past 30 years in where healthcare spend in Canada is allocated. Spending on hospitals and physicians has dropped significantly while spending on drugs has grown to 16 per cent (2010)
Date Published: 22 Aug 2011
The Russian healthcare system is state-run and funded, with about 95 per cent of hospitals belonging to the state. However, the system suffers from a chronic lack of funding, with just 4.5 per cent of GDP being allocated to health, and major fragmentation of services a significant problem.
Date Published: 03 Aug 2011
The influx of Western foods, along with more sedentary lifestyles and stress, are changing the epidemiology of India. These, as well as increasing education and awareness, are increasing demand for treatments for CVD and diabetes. In combination, these factors make India an attractive marketplace for global pharmaceutical companies as growth of the domestic indsutry continues.
Date Published: 20 Jun 2011
Italy emerged from economic recession in 2010 with gross domestic product (GDP) growing one per cent on rising exports; economic growth will, however, be slow and modest until 2015
Date Published: 25 May 2011
Turkey has always been a bridge between Europe and Asia with untapped potential in a variety of industries. With a population of about 75 million and GDP growth of 7.8 per cent based on IMF's 2010 forecast, it represents a unique opportunity for the pharmaceutical industry.
Date Published: 12 Apr 2011
Although the Swedish economy is predominantly based on the exports of raw materials and industrial products, the country also has a strong heritage of pharmaceutical R&D and manufacturing and exported pharmaceutical products at a value of SEK68bn in 2009 (7 per cent of total exports).
